肿瘤药学2023，Vol.13Issue(5)：542-549,8.DOI:10.3969/j.issn.2095-1264.2023.05.03
免疫检查点抑制剂在晚期胸腺上皮肿瘤中的研究进展
Advances in the study of immune checkpoint inhibitors in advanced thymic epithelial tumors
关业兰 1顾晓栋 2郝月 2孙燕 1宋正波1
作者信息
- 1. 温州医科大学,浙江 温州,325035||中国科学院大学附属肿瘤医院/浙江省肿瘤医院,浙江 杭州,310000
- 2. 浙江中医药大学第二临床医学院,浙江 杭州,310000||中国科学院大学附属肿瘤医院/浙江省肿瘤医院,浙江 杭州,310000
- 折叠
摘要
Abstract
Thymic epithelial tumor(TET)is a rare mediastinal malignant tumor.Due to the lack of randomized con-trolled trials,there is no standard treatment in China at present.Surgical resection is the first choice for TETs in early stage,but for unresectable,recurrent or metastatic advanced TETs,comprehensive medical treatment is mainly adopted,including chemotherapy,targeted therapy and immunotherapy.National Comprehensive Cancer Network guidelines recommend plati-num-based combination chemotherapy,but the efficacy is not satisfactory.In recent years,with an in-depth understanding of biology of TETs,more and more studies have focused on the use of immune checkpoint inhibitors(ICIs)such as anti-pro-grammed death 1(PD-1)/programmed death ligand-1(PD-L1)antibodies in TETs.However,due to the unique biological characteristics of TETs,immunotherapy may bring serious immune-related adverse events(irAE).This paper reviewed the clinical studies and case reports of ICIs in the treatment of advanced TETs at home and abroad in recent years,focusing on the efficacy of ICIs and irAEs in the treatment of advanced TETs,so as to provide additional strategies for the treatment of advanced TETs.关键词
胸腺上皮肿瘤/免疫检查点抑制剂/疗效/免疫相关不良反应Key words
Thymic epithelial tumors/Immune checkpoint inhibitors/Efficacy/Immune-related adverse events分类
医药卫生引用本文复制引用
关业兰,顾晓栋,郝月,孙燕,宋正波..免疫检查点抑制剂在晚期胸腺上皮肿瘤中的研究进展[J].肿瘤药学,2023,13(5):542-549,8.
